First human trial of PRL3-ZUMAB aims to find safe dose for advanced cancers
NCT ID NCT03191682
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 37 times
Summary
This study is the first time PRL3-ZUMAB is being tested in humans. It aims to find a safe dose for people with advanced solid tumors that have stopped responding to standard treatments. The trial will enroll 38 participants and monitor for side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital
Singapore, Singapore, 119.074, Singapore
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRL3-ZUMAB (an experimental antibody drug)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 38 participants, focused on safety and dosing. The drug may not shrink tumors or may cause side effects, and it is far from being proven effective.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.